CLOROX CO /DE/ (CLX)

Current Report Filed: 2026-05-11

Key Insights

Clorox raised $1.5 billion in a registered public offering across three senior note tranches with maturities ranging from 2031 to 2036, indicating the company is strengthening its balance sheet and extending debt maturity profile.
The interest rates on the new notes (4.700% to 5.250%) reflect current market conditions and the company's credit quality, with rates increasing proportionally with longer maturities, suggesting investor confidence in Clorox's creditworthiness.
This debt issuance may support strategic initiatives, debt refinancing, or provide financial flexibility for capital allocation, though the specific use of proceeds is not disclosed in this 8-K filing.

Insider Trading Filed: 2026-05-05

Key Insights

Director Pierre R Breber purchased 5,000 shares of CLX at a weighted average price of $85.82 on 05/05/2026, executed across multiple trades ranging from $85.19 to $86.01, indicating measured accumulation rather than aggressive buying.
Breber's total beneficial ownership after the transaction stands at 18,000 shares held indirectly through a trust, suggesting a significant long-term stake in the company as a board director.
The purchase represents a modest insider investment of approximately $429,124, which is a positive signal of insider confidence but not a substantial buying commitment that would indicate major bullish expectations.
As a director (not an officer), Breber's transaction does not trigger heightened scrutiny under Form 4 requirements, though the execution method with multiple trades demonstrates careful transaction execution.

Quarterly Report Filed: 2026-04-30

Key Insights

The filing indicates Clorox completed divestiture activity during the period, including the sale of the Vitamins, Minerals and Supplements business (disposed in Q3 2025), and the Glad business was still held for sale as of March 31, 2026, suggesting portfolio restructuring to focus on core operations.
Multiple derivative instruments are in place (commodity contracts, foreign exchange forwards, interest rate contracts) indicating active hedging of commodity price volatility and foreign exchange exposure, which is critical given Clorox's exposure to raw material and international operations.
The company maintains multiple credit facilities including revolving credit agreements and delayed draw term loans as of March 31, 2026, providing financial flexibility for operations and strategic initiatives, though specific debt levels and liquidity position require review of balance sheet details.

Current Report Filed: 2026-04-30

Key Insights

Clorox announced Q3 2026 financial results for the quarter ended March 31, 2026, with detailed press release and supplemental financial information provided to investors via standard 8-K disclosure.
The filing was signed by Angela Hilt, Executive Vice President and Chief Legal Officer, indicating proper corporate authorization and governance of the earnings announcement.
This is a routine quarterly earnings disclosure filed in compliance with Regulation FD, containing no material agreements, leadership changes, or other non-routine events that would warrant special investor attention.

Insider Trading Filed: 2026-04-03

Key Insights

Luc Bellet, the EVP and Chief Financial Officer of Clorox Co, sold 244 shares of the company's common stock on April 1, 2026 at a price of $103.63 per share.
Following the reported transaction, Bellet now beneficially owns 20,638 shares of Clorox, down from 20,882 shares previously.
The share sale was due to the withholding of shares by the company to satisfy tax obligations applicable to the vesting of restricted stock.

Insider Trading Filed: 2026-04-02

Key Insights

The reporting person, Christopher J. Williams, has acquired additional Deferred Stock Units in Clorox (CLX) through dividend reinvestment and as compensation for his role as a Director.
The acquired Deferred Stock Units will be settled 100% in Clorox common stock upon Williams' retirement or other termination of service as a Director.
The increase in Deferred Stock Unit holdings suggests Williams' continued commitment to Clorox and confidence in the company's long-term prospects.

Insider Trading Filed: 2026-04-02

Key Insights

The reporting person, Russell J. Weiner, acquired 172.363 deferred stock units through dividend reinvestment and 325.6779 deferred stock units in lieu of director's fees, indicating increased ownership stake in the company.
The deferred stock units will be settled 100% in Clorox stock upon the reporting person's retirement or other termination of service as a director, suggesting a long-term investment perspective.
The reporting person's ownership of deferred stock units has increased to 18,004.0034, indicating a significant and growing economic interest in Clorox's performance.

Insider Trading Filed: 2026-04-02

Key Insights

Insider Matthew J. Shattock, a director of Clorox, has increased his beneficial ownership of the company's stock through the acquisition of additional deferred stock units.
The deferred stock units were acquired through dividend reinvestment and in lieu of quarterly director's fees, indicating that Shattock is committed to the long-term growth of Clorox.
Shattock's increased stake in the company suggests he has a positive outlook on Clorox's future prospects and aligns his interests with those of other shareholders.

Insider Trading Filed: 2026-04-02

Key Insights

The reporting person, Pierre R. Breber, acquired additional deferred stock units (DSUs) in Clorox Co (CLX) through dividend reinvestment and director fee payments, indicating their continued investment in the company.
The total number of DSUs beneficially owned by the reporting person increased from 2,774.3895 to 3,100.0674, suggesting an increased ownership stake in the company.
The acquisition of DSUs is a common practice for directors, as they are often compensated in the form of equity-based awards that are settled in the company's common stock upon retirement or termination of service.

Insider Trading Filed: 2026-04-02

Key Insights

Stephanie Plaines, a director of Clorox Co, has acquired additional deferred stock units through dividend reinvestment and director's fee payments, indicating their continued confidence in the company.
The reporting of these transactions provides transparency into the insider ownership and sentiment at Clorox.
The acquisition of these shares aligns the director's interests with those of shareholders, as the deferred stock units will be settled in Clorox's common stock upon retirement or termination of service.

Current Report Filed: 2026-04-01

Key Insights

Clorox has completed the acquisition of GOJO Industries, the maker of Purell, a leading brand in the hand sanitizer and hygiene products market.
The acquisition of GOJO Industries aligns with Clorox's strategy to expand its portfolio of essential consumer products and strengthen its position in the growing hygiene and disinfection category.
The transaction is likely to provide Clorox with new growth opportunities and synergies as it integrates GOJO's products and operations with its existing business.

Insider Trading Filed: 2026-03-17

Key Insights

The reporting person, Chris T. Hyder, an EVP-Group President of Health & Hygiene at Clorox Co, disposed of 41 shares of common stock through a withholding to satisfy tax obligations related to the vesting of restricted stock.
Following the reported transaction, Hyder now beneficially owns 34,969 shares of Clorox Co common stock, indicating continued ownership and commitment to the company.
The transaction was made on March 13, 2026, which is the date of the earliest transaction reported in the filing.

Insider Trading Filed: 2026-03-17

Key Insights

The reporting person, Stacey Grier, is an EVP and Executive Chief of Staff at Clorox Co, indicating that this is a high-level insider transaction.
Grier disposed of 32 shares of Clorox common stock at $108.73 per share, likely to cover tax obligations related to vesting of restricted stock.
The transaction is relatively small, representing a minor change in Grier's overall beneficial ownership of 32,116 Clorox shares.

Current Report Filed: 2026-03-10

Key Insights

Clorox is acquiring GOJO Industries, the maker of PURELL, in a significant transaction that will expand its consumer health and wellness portfolio.
The company has secured $2.25 billion in new credit facilities, including a $1 billion 364-day revolving credit agreement and a $1.25 billion delayed draw term credit agreement, to finance the acquisition and support general corporate purposes.
The credit agreements contain customary covenants and events of default, with the key financial covenant being a consolidated interest coverage ratio.

Quarterly Report Filed: 2026-02-03

Key Insights

The company reported a 5% decline in revenue for the second quarter of fiscal year 2026 compared to the prior year period, indicating potential headwinds in the business.
Gross margin decreased by 200 basis points year-over-year, suggesting pressure on profitability, which may impact the company's financial performance.
The company announced the divestiture of its Vitamins, Minerals, and Supplements business segment, which could signal a strategic shift in the company's focus and product portfolio.

Current Report Filed: 2026-02-03

Key Insights

Clorox reported Q2 2025 financial results, with details on revenue, earnings, and other key metrics.
The company provided an update on its business operations and any notable events or developments during the quarter.
Investors should review the supplemental financial information provided to gain additional context around the quarterly performance.

Current Report Filed: 2026-01-22

Key Insights

Clorox announced the acquisition of GOJO Industries, Inc., the maker of PURELL, for $2.25 billion in cash, which is expected to significantly expand Clorox's presence in the hand sanitizer and personal hygiene product categories.
The acquisition is expected to be funded primarily through debt financing and is subject to regulatory approval and other customary closing conditions.
Clorox reaffirmed its fiscal year 2026 outlook for net sales, diluted EPS, and adjusted EPS, indicating the company's confidence in its financial performance despite the acquisition.

Insider Trading Filed: 2026-01-05

Key Insights

Gina Boswell, a director of Clorox Co, has received an annual award of 825.0862 deferred stock units as part of the company's 2005 Stock Incentive Plan.
The deferred stock units will be settled 100% in Clorox common stock upon Boswell's retirement or other termination of service as a director.
This filing indicates ongoing management and board-level alignment with Clorox's long-term strategic direction through the granting of equity-based compensation to directors.

Insider Trading Filed: 2026-01-05

Key Insights

The reporting person, Christopher J. Williams, has acquired additional deferred stock units in Clorox Co through dividend reinvestment and director compensation, indicating continued confidence in the company.
The total amount of deferred stock units beneficially owned by the reporting person has increased from 19,685.9816 to 21,596.5756, suggesting a positive long-term outlook.
The reported transactions were made pursuant to the company's stock incentive plan and director compensation policy, which is in line with standard corporate governance practices.

Insider Trading Filed: 2026-01-05

Key Insights

The reporting person, Russell J. Weiner, who is a director of Clorox Co, has acquired 1,637.8577 deferred stock units on 12/31/2025 as an annual award under the 2005 Stock Incentive Plan.
Weiner has also acquired 334.7218 deferred stock units on 12/31/2025 in lieu of receiving quarterly director's fees.
The deferred stock units will be settled 100% in Clorox stock upon Weiner's retirement or other termination of service as a director.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information